Human 3D Organoid Models Advance Mechanistic Understanding of Motor Neuron Diseases
核心洞察
Neuromuscular organoids and spinal cord organoids derived from human iPSCs now recapitulate key pathological features of ALS and SMA, including NMJ degeneration and glial dysfunction.
Patient-derived organoid models enable mutation-specific interrogation of motor neuron disease mechanisms, revealing targetable pathways such as HDAC6 inhibition and cell cycle re-entry.
Recent advances in assembloid technology integrate cortical, spinal cord, and skeletal muscle tissues, demonstrating functional corticospinal connectivity and optogenetically evoked muscle contractions.
The convergence of induced pluripotent stem cell (iPSC) technology and three-dimensional organoid culture is transforming the study of motor neuron diseases, offering unprecedented opportunities to model amyotrophic lateral sclerosis (搜索) (ALS) and spinal muscular atrophy (搜索) (SMA) in human-relevant systems. A comprehensive review published in Nature Reviews Neuroscience details how human 3D organoid models are providing mechanistic insights that have long eluded researchers relying on traditional two-dimensional cultures and animal models.
The field has progressed rapidly from the foundational work of Lancaster and colleagues, who demonstrated that pluripotent stem cells could self-organize into complex brain-like structures, to sophisticated multi-tissue assembloids that recapitulate the entire neuromuscular axis. Faustino Martins et al. established a landmark self-organizing neuromuscular organoid model derived from neuromesodermal progenitors, integrating spinal cord, skeletal muscle, and functional neuromuscular junction-like structures that recapitulate thoracolumbar axial identity.
Recapitulating Disease Pathology in a Dish
Patient-derived organoid models now capture hallmark pathologies of both ALS and SMA. Pereira and colleagues established the first human ALS sensorimotor organoid model from patient-derived and isogenic iPSCs, enabling mutation-specific interrogation of neuromuscular junction dysfunction, impaired muscle contraction, and altered innervation within a functionally connected human sensorimotor system. Gao et al. subsequently established a C9orf72 neuromuscular organoid platform that models progressive ALS-related neuromuscular pathology, including NMJ degeneration, glial alterations, and age-dependent disease phenotypes.
For SMA, Hor and colleagues pioneered the first human ventral spinal cord organoid model derived from neural progenitor cells, recapitulating spinal motor neuron identity and identifying aberrant cell cycle re-entry as a therapeutically targetable mechanism. More recently, Grass et al. demonstrated that isogenic patient-derived organoids reveal early neurodevelopmental defects in SMA initiation, while Faravelli and colleagues showed that SMA spinal cord organoids exhibit developmental and electrophysiological abnormalities that can be partially rescued by antisense oligonucleotide-mediated SMN (搜索) restoration.
Integrating Glial and Immune Contributions
The organoid field is increasingly recognizing that motor neuron diseases are not cell-autonomous. Astrocytes derived from ALS patients with C9ORF72 mutations show increased oxidative stress and neurotoxicity, as demonstrated by Birger and colleagues. Stoklund Dittlau and Van Den Bosch have emphasized the critical importance of astrocytes in motor neuron disease pathogenesis. Taha et al. further showed that astrocytes display cell-autonomous and diverse early reactive states in familial ALS.
Microglial involvement is also gaining attention. Recent work by Masrori et al. demonstrated that C9orf72 hexanucleotide repeat expansions impair microglial response in ALS, while Clarke and Patani provided a comprehensive analysis of the microglial component of ALS. The development of neuroimmune assembloids incorporating microglia and T cells now enables investigation of immune dysregulation within physiologically relevant 3D environments.
Bioengineering Advances Driving Reproducibility
A major challenge for the field has been organoid variability. Recent bioengineering innovations are addressing this limitation. Roth and colleagues developed a magnetically guided bioengineering platform enabling high-precision spatial assembly of iPSC-derived neural organoids with minimal structural deformation. Yaman and Ramanathan integrated bioengineering and machine learning strategies to improve organoid reproducibility and spatial organization, generating elongated trunk-like organoids with coordinated neural tube-somite architecture.
Gribaudo et al. generated elongated self-organizing human trunk-like organoids from iPSCs that recapitulate coordinated neural-mesodermal morphogenesis and region-specific neural patterning. Lee and colleagues produced human spinal cord organoids that recapitulate self-organized neural tube morphogenesis and dorsoventral patterning, establishing a developmentally faithful platform for modeling early human spinal cord development.
Decellularized extracellular matrix scaffolds are further enhancing organoid fidelity. Sun et al. demonstrated that harnessing developmental dynamics of spinal cord extracellular matrix improves the regenerative potential of spinal cord organoids, while Auletta and colleagues showed that native extracellular matrix promotes human neuromuscular organoid morphogenesis and function.
Functional Readouts and Therapeutic Screening
The Andersen laboratory pioneered the first functional human cortico-motor assembloid model by integrating cortical organoids with spinal cord and skeletal muscle spheroids, demonstrating long-range corticospinal connectivity and optogenetically evoked muscle contractions in a human stem cell-derived system. Osaki and colleagues developed a microfluidic NMJ-on-chip model linking ALS-associated motor neuron pathology to impaired muscle contraction and neurotoxicity.
These functional platforms are increasingly being deployed for therapeutic screening. HDAC6 inhibition has emerged as a promising target, with Fazal et al. demonstrating that HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations, and Stoklund Dittlau et al. showing that FUS (搜索)-mutant motor units in microfluidic devices are improved by HDAC6 inhibition.
The integration of multi-omics approaches with organoid technology, as advocated by Morello and colleagues for precision medicine in ALS, promises to further stratify disease subtypes and identify patient-specific therapeutic vulnerabilities. As the field moves toward incorporating vascularization, aging signatures, and high-throughput screening capabilities, human 3D organoid models are poised to become indispensable tools in the development of effective therapies for motor neuron diseases.